Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: H.P. Acthar Gel (repository corticotropin injection) Clear all

Conditions: Rheumatoid Arthritis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: Iraj Sabahi Research Inc.; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Pleasanton, California • Turlock, California

Conditions: Lupus Erythematosus Systemic Exacerbation
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Diabetic Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 10
States / cities: Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more

Conditions: Proliferative Vitreoretinopathy
Interventions: Adrenocorticotropic Hormone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoidosis
Interventions: Repository Corticotropin Injection; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: West Syndrome
Interventions: adrenocorticotropin hormone; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 2 Months to 12 Months
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Proteinuria, Idiopathic Membranous Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more

Conditions: Sarcoidosis, Pulmonary
Interventions: Acthar Gel, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Dry Eye Disease
Interventions: Corticotropin 80Unit/Ml Repository Injection; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Sclerosis
Interventions: Acthar Gel; Drug
Lead sponsor: Tanner Foundation for Multiple Sclerosis; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Acthar Gel, Placebo; Drug
Lead sponsor: Mallinckrodt ARD LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Acthar, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Acthar Gel, Placebo Gel; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Hemet, California • Upland, California • Fort Lauderdale, Florida + 12 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: H.P. Acthar® Gel; Drug
Lead sponsor: Mamatha Pasnoor, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more

Conditions: End Stage Renal Disease
Interventions: Acthar Gel; Drug
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Chronic Migraine
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: Dent Neuroscience Research Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more

Conditions: Multiple Sclerosis
Interventions: repository corticotropin injection, Saline; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions: Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis
Interventions: Acthar Gel; Drug
Lead sponsor: Aaron Miller; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis (MS)
Interventions: H.P. Acthar Gel (repository corticotropin injection); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Oceanside, California • Houston, Texas

Conditions: Uveitis, Posterior, Vasculitis Retinal
Interventions: H.P. ACTHAR GEL; Drug
Lead sponsor: Ocular Immunology and Uveitis Foundation; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: ACTH, Placebo; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Repository corticotropin injection; Drug
Lead sponsor: Arthritis Treatment Center, Maryland; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Frederick, Maryland

Search by objective public record fields.

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

ACTHAR Therapy for Central Nervous System Sarcoidosis

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Acthar Gel in Participants With Pulmonary Sarcoidosis

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

Comprehensive Analysis of Relapse in Multiple Sclerosis

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

ACTH for Fatigue in Multiple Sclerosis Patients

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.